Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1629-1636

  Seymour, Leonard W ^a,j   Ferry, David R ^a,k   Kerr, David J ^a,j   Rea, Daniel ^a   Whitlock, Maggie ^a   Poyner, Richard ^b   Boivin, Christopher ^b   Hesselewood, Stuart ^c   Twelves, Christopher ^d,l   Blackie, Robert ^d   Schatzlein, Andreas ^d,m   Jodrell, Duncan ^e   Bissett, Donald ^f   Calvert, Hilary ^g   Lind, Mike ⁿ   Robbins, Adele ^h   Burtles, Sally ^h   Duncan, Ruth ⁱ   Cassidy, James ^d,f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ School of Pharmacy   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k NEW CROSS HOSPITAL   (United Kingdom)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^m UNIVERSITY OF LONDON   (United Kingdom)

ⁿ Department of Academic Oncology   (United Kingdom)

more..

Author keywords

N (2 hydroxypropyl)meth acrylamide copolymer conjugates; Drug targeting EPR effect; Polymeric produgs

Indexed keywords

DOXORUBICIN DERIVATIVE; FCE 28068; IODINE 123; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HOT FLUSH; HUMAN; IMAGE ANALYSIS; INFECTION; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POTASSIUM DEFICIENCY; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY EXCRETION;

ACRYLAMIDES; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 67649417879     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000293     Document Type: Article

References (33)

1. Ehrlich P: Chemotherapeutics: scientific principles, methods, and results. Lancet 2: 445-451, 1913.
2. Maeda H, Seymour LW and Miyamoto Y: Conjugates of anti-cancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3: 351-362, 1992.
3. Thanou M and Duncan R: Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs 4: 701-709, 2003.
4. Duncan R: The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347-360, 2003.
5. Seymour LW: Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187, 1992.
6. Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392, 1986.
7. Duncan R: Polymer conjugates for tumour targeting and intra-cytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technolo Today 2: 441-449, 1999.
8. Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J and Duncan R: Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer 70: 636-641, 1994.
9. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E and Cassidy J: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5: 83-94, 1999.
10. Thomson AH, Vasey PA, Murray LS, Cassidy J, Fraier D, Frigerio E and Twelves C: Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer 81: 99-107, 1999.
11. Rejmanova P, Pohl J, Baudys M, Kostka V and Kopecek J: Degradation of oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers by bovine spleen cathepsin. Makromol Chem B 184: 2009-2016, 1983.
12. Duncan RSL, Flanagan PA, O'Hare KB, Wedge SR, Ulbrich K, Strohalm J, Subr V, Spreafico F, Grandi M, Ripamonti M, Farao M and Suarato A: Preclinical evaluation of polymer-bound doxorubicin. J Controlled Release 19: 331-342, 1992.
13. Jones AT, Gumbleton M and Duncan R: Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv Drug Deliv Rev 55: 1353-1357, 2003.
14. Pimm MV, Perkins AC, Strohalm J, Ulbrich K and Duncan R: Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J Drug Target 3: 385-390, 1996.
15. Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S and Kerr DJ: Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release 57: 281-290, 1999.
16. Praga C: Co-operative clinical study of adriamycin in advanced lung tumours. In: International Symposium on Adriamycin. DKaG M (ed). Springer Verlag, Berlin, pp173-179, 1972.
17. Bonadonna G, De Lena M and Beretta G: Preliminary clinical screening with adriamycin in lung cancer. Eur J Cancer 7: 365-367, 1971.
18. Cummings J and Smyth JF: Pharmacology of adriamycin: the message to the clinician. Eur J Cancer Clin Oncol 24: 579-582, 1988.
19. Conley BA, Egorin MJ, Whitacre MY, Carter DC, Zuhowski EG and van Echo DA: Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol 33: 107-112, 1993.
20. Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Kredtke S, Voliotis D, Scheulen ME, Seeber S and Strumberg D: A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther 41: 620-621, 2003.
21. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G and Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89: 1037-1047, 2000.
22. Cummings J and McArdle CS: Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 53: 835-838, 1986.
23. Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M, Beijnen JH, Schellens JH and ten Bokkel Huinink WW: A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 87: 608-614, 2002.
24. Sarapa N, Britto MR, Speed W, Jannuzzo M, Breda M, James CA, Porro M, Rocchetti M, Wanders A, Mahteme H and Nygren P: Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol 52: 424-430, 2003.
25. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271: 58-65, 1994.
26. Vicent MJ, Manzanaro S, De la Fuente JA and Duncan R: HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics. J Drug Target 12: 503-515, 2004.
27. Vicent MJ, Tomlinson R, Brocchini S and Duncan R: Poly-acetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation. J Drug Target 12: 491-501, 2004.
28. Ulbrich K, Etrych T, Chytil P, Jelinkova M and Rihova B: Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 12: 477-489, 2004.
29. Pechar M, Braunova A, Ulbrich K, Jelinkova M and Rihova B: Poly(ethylene glycol)-doxorubicin conjugates with pH-controlled activation. J Bioactive Compatible Polymers 20: 319-342, 2005.
30. Saito G, Swanson JA and Lee KD: Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 55: 199-215, 2003.
31. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S and Kerr DJ: Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676, 2002.
32. Meerum Terwogt JM, Ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ and Beijnen JH: Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315-323, 2001.
33. Veronese ML, Flaherty K, Kramer A, Konkle BA, Morgan M, Stevenson JP and O'Dwyer PJ: Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol 55: 497-501, 2005.